About: Assessment of the Evolution of Cancer Treatment Therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessment of the Evolution of Cancer Treatment Therapies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Assessment of the Evolution of Cancer Treatment Therapies
Creator	Arruebo, Manuel González-Fernández, África Lambea, Julio Sáez-Gutierrez, Berta Tres, Alejandro Valladares, Mónica Vilaboa, Nuria
Source	PMC
abstract	Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.
has issue date	2011-08-12(xsd:dateTime)
bibo:doi	10.3390/cancers3033279
bibo:pmid	24212956
has license	cc-by
sha1sum (hex)	a71052d0d97adb979510b675275149d05cd7976e
schema:url	https://doi.org/10.3390/cancers3033279
resource representing a document's title	Assessment of the Evolution of Cancer Treatment Therapies
has PubMed Central identifier	PMC3759197
has PubMed identifier	24212956
schema:publication	Cancers (Basel)
resource representing a document's body	covid:a71052d0d97adb979510b675275149d05cd7976e#body_text
is schema:about of	named entity 'CANCER TREATMENT' named entity 'DIRECTED' named entity 'EITHER' named entity 'THERAPEUTIC' named entity 'EVOLUTION' named entity 'COMBINING' named entity 'CURE' named entity 'DOWNS' named entity 'NEW' named entity 'IMAGING' named entity 'SURGERY' named entity 'SIDE EFFECTS' named entity 'OFFERING' named entity 'BUT' named entity 'ASSESSMENT' named entity 'HYPERTHERMIA' named entity 'HISTORY' named entity 'THERAPIES' named entity 'HOPE' named entity 'ARRIVED' named entity 'TARGET' named entity 'CONTROLLED DRUG DELIVERY' named entity 'CASE' named entity 'IMMUNOTHERAPY' named entity 'COMPONENTS' named entity 'COMPLETE REMISSION' named entity 'YEARS' named entity 'DRUGS' named entity 'RECENTLY' named entity 'CHARACTERIZED' named entity 'THESE' named entity 'NANOSTRUCTURES' named entity 'DUE TO' named entity 'APPLIED' named entity 'REALITY' named entity 'CASES' named entity 'SCENE' named entity 'THERAPIES' named entity 'RECENT' named entity 'IMPORTANT' named entity 'COMBINATION' named entity 'PROVIDING' named entity 'TREATMENT' named entity 'ANTITUMOR' named entity 'CANCER THERAPY' named entity 'RADIATION' named entity 'NANOTECHNOLOGY' named entity 'TREATMENTS' named entity 'SOLID TUMORS' named entity 'ARSENAL' named entity 'UPS' named entity 'APPLYING' named entity 'CHOICE' named entity 'THERAPY' named entity 'HAVE' named entity 'THERAPEUTIC ALTERNATIVE' named entity 'Evolution' named entity 'tumor cells' named entity 'oncology' named entity 'scFv' named entity 'disease-free survival' named entity '60,000' named entity 'Mad Cow Disease' named entity 'genetic studies' named entity 'cancer therapies' named entity 'myeloma' named entity 'snake venom' named entity 'animal models' named entity 'tumor' named entity 'antibodies' named entity 'clinical trials' named entity 'extracellular' named entity 'nanoparticle' named entity 'chemotherapy agent' named entity 'methotrexate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software